In vitro responsiveness of human asthmatic bronchus to carbachol, histamine, beta‐adrenoceptor agonists and theophylline.

RG Goldie, D. Spina, PJ Henry, KM Lulich, JW Paterson

Research output: Contribution to journalArticle

189 Citations (Scopus)

Abstract

Responses of human bronchial strip preparations to contractile and relaxant agonists were measured in preparations from non‐diseased and from asthmatic lung obtained 3‐15 h post‐mortem. The potencies of carbachol and histamine were approximately two times less in asthmatic than in non‐diseased bronchi. This was statistically significant for carbachol (P less than 0.05), but not for histamine (P greater than 0.05). These results clearly indicate that the bronchial hyperreactivity to airway spasmogens observed in asthma is exclusively an in vivo phenomenon not involving increasing sensitivity of bronchial smooth muscle. The potencies of the beta‐adrenoceptor agonists isoprenaline, fenoterol and terbutaline were significantly reduced by 4‐ 5 fold in asthmatic bronchi compared with non‐diseased airways. In contrast, theophylline was equipotent in the two populations of airway preparations. Thus, it appears that severe asthma is associated with decreased bronchial smooth muscle beta 2‐adrenoceptor function. 1986 The British Pharmacological Society

Original languageEnglish
Pages (from-to)669-676
Number of pages8
JournalBritish Journal of Clinical Pharmacology
Volume22
Issue number6
DOIs
Publication statusPublished - 1 Jan 1986

Fingerprint

Histamine Agonists
Carbachol
Bronchi
Theophylline
Histamine
Smooth Muscle
Asthma
Fenoterol
Bronchial Hyperreactivity
Terbutaline
Isoproterenol
Lung
Population
In Vitro Techniques

Cite this

@article{6671f6178cb8498c877925b8f043fb08,
title = "In vitro responsiveness of human asthmatic bronchus to carbachol, histamine, beta‐adrenoceptor agonists and theophylline.",
abstract = "Responses of human bronchial strip preparations to contractile and relaxant agonists were measured in preparations from non‐diseased and from asthmatic lung obtained 3‐15 h post‐mortem. The potencies of carbachol and histamine were approximately two times less in asthmatic than in non‐diseased bronchi. This was statistically significant for carbachol (P less than 0.05), but not for histamine (P greater than 0.05). These results clearly indicate that the bronchial hyperreactivity to airway spasmogens observed in asthma is exclusively an in vivo phenomenon not involving increasing sensitivity of bronchial smooth muscle. The potencies of the beta‐adrenoceptor agonists isoprenaline, fenoterol and terbutaline were significantly reduced by 4‐ 5 fold in asthmatic bronchi compared with non‐diseased airways. In contrast, theophylline was equipotent in the two populations of airway preparations. Thus, it appears that severe asthma is associated with decreased bronchial smooth muscle beta 2‐adrenoceptor function. 1986 The British Pharmacological Society",
author = "RG Goldie and D. Spina and PJ Henry and KM Lulich and JW Paterson",
year = "1986",
month = "1",
day = "1",
doi = "10.1111/j.1365-2125.1986.tb02956.x",
language = "English",
volume = "22",
pages = "669--676",
journal = "British Journal Clinical Pharmacology",
issn = "0306-5251",
publisher = "John Wiley & Sons",
number = "6",

}

In vitro responsiveness of human asthmatic bronchus to carbachol, histamine, beta‐adrenoceptor agonists and theophylline. / Goldie, RG; Spina, D.; Henry, PJ; Lulich, KM; Paterson, JW.

In: British Journal of Clinical Pharmacology, Vol. 22, No. 6, 01.01.1986, p. 669-676.

Research output: Contribution to journalArticle

TY - JOUR

T1 - In vitro responsiveness of human asthmatic bronchus to carbachol, histamine, beta‐adrenoceptor agonists and theophylline.

AU - Goldie, RG

AU - Spina, D.

AU - Henry, PJ

AU - Lulich, KM

AU - Paterson, JW

PY - 1986/1/1

Y1 - 1986/1/1

N2 - Responses of human bronchial strip preparations to contractile and relaxant agonists were measured in preparations from non‐diseased and from asthmatic lung obtained 3‐15 h post‐mortem. The potencies of carbachol and histamine were approximately two times less in asthmatic than in non‐diseased bronchi. This was statistically significant for carbachol (P less than 0.05), but not for histamine (P greater than 0.05). These results clearly indicate that the bronchial hyperreactivity to airway spasmogens observed in asthma is exclusively an in vivo phenomenon not involving increasing sensitivity of bronchial smooth muscle. The potencies of the beta‐adrenoceptor agonists isoprenaline, fenoterol and terbutaline were significantly reduced by 4‐ 5 fold in asthmatic bronchi compared with non‐diseased airways. In contrast, theophylline was equipotent in the two populations of airway preparations. Thus, it appears that severe asthma is associated with decreased bronchial smooth muscle beta 2‐adrenoceptor function. 1986 The British Pharmacological Society

AB - Responses of human bronchial strip preparations to contractile and relaxant agonists were measured in preparations from non‐diseased and from asthmatic lung obtained 3‐15 h post‐mortem. The potencies of carbachol and histamine were approximately two times less in asthmatic than in non‐diseased bronchi. This was statistically significant for carbachol (P less than 0.05), but not for histamine (P greater than 0.05). These results clearly indicate that the bronchial hyperreactivity to airway spasmogens observed in asthma is exclusively an in vivo phenomenon not involving increasing sensitivity of bronchial smooth muscle. The potencies of the beta‐adrenoceptor agonists isoprenaline, fenoterol and terbutaline were significantly reduced by 4‐ 5 fold in asthmatic bronchi compared with non‐diseased airways. In contrast, theophylline was equipotent in the two populations of airway preparations. Thus, it appears that severe asthma is associated with decreased bronchial smooth muscle beta 2‐adrenoceptor function. 1986 The British Pharmacological Society

UR - http://www.scopus.com/inward/record.url?scp=0022978869&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2125.1986.tb02956.x

DO - 10.1111/j.1365-2125.1986.tb02956.x

M3 - Article

VL - 22

SP - 669

EP - 676

JO - British Journal Clinical Pharmacology

JF - British Journal Clinical Pharmacology

SN - 0306-5251

IS - 6

ER -